FLASH SPRING SALE: 50% Off Premium Subscription >> FLASH SPRING SALE: 50% Off Premium >>
$1.97
+0.0300 (+1.55%)
At Close: Apr 29, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile
There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:
Click to get the best stock tips daily for free!

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in... PRQR Profile

Golden Star

Ticker Date Change Price
DHT Apr 24 1.95% $11.28
MLI Apr 19 11.07% $52.28
LPLA Apr 19 4.31% $262.59
DOOR Apr 18 0.90% $131.39
PFLT Apr 18 1.78% $11.25
LNG Apr 17 3.12% $156.81
FCN Apr 16 2.83% $207.62
ELV Apr 16 5.33% $506.97
AKR Apr 05 6.47% $16.53
ITCI Apr 05 5.64% $68.44
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT